This assumption is supported by the observations on the synergism between the anti-PD1 antibody and synthetic α-gal micelles in preventing metastases’ development in anti-Gal-producing mice carrying B16 melanoma [42] and may be further supported by future clinical trials combining the two treatments. This evidence concerns the gene GAL and melanoma.